Navigation Links
Synthetic cocoa chemical slows growth of tumors in human cell lines
Date:6/13/2008

Washington, D.C. A synthetic chemical based on a compound found in cocoa beans slowed growth and accelerated destruction of human tumors in laboratory studies, and should be tested further for cancer chemoprevention or even treatment, say researchers at Georgetown University Medical Center.

"We have all heard that eating chocolate is good for you; this study suggests one reason why that might be true," says the study's lead author Min Kim, Ph.D., a research scientist in the Department of Oncology at Lombardi Comprehensive Cancer Center.

Published online today in Cell Cycle, the researchers describe how four different human tumor cells lines out of 16 tested were sensitive to the chemical, known as GECGC. The strongest response was seen in two different colon cancers; growth was cut in half and most of the tumor cells were damaged.

Normal cells were not affected by GECGC, which makes the chemical a candidate for cancer chemoprevention, says Kim.

"This chemical seems to be safe, which makes sense because it has a structure similar to a natural product in cocoa beans - the same beans that are used to make chocolate," he says.

The researchers have long studied the beneficial effects of flavanols, which are molecules in vegetables and fruits that exhibit potent anti-oxidant and, potentially, anti-tumor properties. As part of these studies, investigators have been testing a new synthetic version of natural procyanidins, a class of flavanols, created and patented by the confectionery company, Mars Incorporated. (The company provided GECGC as a gift, and this project was funded in part by Mars Incorporated.)

In these studies, the scientists tested the effects of three different doses of GECGC on the cancer cell lines - the first time that a synthetic cocoa derivative has been used to screen human cancer cell lines. None of the doses tested were extreme, Kim points out. "The effective concentrations were considere
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
414-312-7085
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Chloroplast f and m Thioredoxins Discovered in Nonphotosynthetic Tissues
2. Synthetic compound promotes death of lung-cancer cells, tumors
3. Experts from Stevens, Merck, publish joint paper, Biosynthetic Studies of Platensimycin
4. Researchers decode genetics of rare photosynthetic bacteria
5. Researchers decode genetics of rare photosynthetic bacterium
6. Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find
7. Berkeley researchers identify photosynthetic dimmer switch
8. Oregano oil works as well as synthetic insecticides to tackle common beetle pest
9. New projects to raise UK profile in synthetic biology
10. Synthetic Biology: funders move to address social and ethical challenges
11. Natural compounds in cocoa tied to blood flow improvements for adults with type 2 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ousands of years it has been prescribed by traditi...s from headaches and stomach pain to fever and flu...tle University have been able to scientifically pr...ta otherwise known as Brazilian mint. , Testing...m led by researcher Graciela Rocha was able to sho...
(Date:11/24/2009)... that keep weakened and flabby arteries from colla...nths, those stents are no longer needed -- once th...ry. Previously, doctors had no choice but to leave...Aviv University,s Department of Biomedical Enginee...form that carries drugs where they,re needed, then...
(Date:11/24/2009)...N ROUGE Antarctica has long held secrets of the e... recently, there has been very little information ...miles of ice for millions of years. Now, a team of... have been funded to the tune of $10 million doll... get to the bottom of things literally. These sci...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 1Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 2Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 3Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 4Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 5Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 1Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 2Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 3China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 1China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 2China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 3
...n a mud flat at the edge of the Cocheco River, jus...ersity of New Hampshire,s Contaminated Sediments C...ted sediment in coastal waterways. , Rather than ...al feet of sand, they,ve created a patch black ge...ion in place. Over the next two years, UNH associa...
... is available in German . , Infectious proteins... of "mad cow" disease (BSE). The culprits are "inc...y proteins. The molecular bases for such prion dis...roteins infectious while others are not? A team he...aimon Sabat (University of Bordeaux, France) has e...
...f., June 16 Authernative, Inc., a,leading develop...management,technologies, announced today that it h...n (GSA) Information Technology Schedule contract, ...tive to sell its AuthGuard(R),user authentication ... Schedule contract, which represents Authernative,...
Other Biology News:UNH researchers test sediment-scrubbing technology in NH river 2UNH researchers test sediment-scrubbing technology in NH river 3Tracking prions 2Authernative Awarded GSA Schedule Contract 2Authernative Awarded GSA Schedule Contract 3
(Date:11/24/2009)...w York investment bank KTA Capital,s client Neuren...7 mil convertible note private placement with a U....as arranged by KTA Capital as Neuren,s exclusive p... New York (PRWEB) November 23, 2009 -- The ind... ("KTA Capital") has announced that its ...
(Date:11/24/2009)...re-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SI...day,December1stat1:45PMGMTinLondon,7:45AMUS/CST.In...heInternetavailableat http://inve s tor.sig m ...toaccessthisfile. ,, AboutSigma-Aldrich: Sig...mpany.Itschemicalandbiochemicalproductsandkitsareu...
(Date:11/24/2009)...RNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ...ommercializingnovelpainmanagementtherapies,announc...veOfficer,isscheduledtopresentatthe21stAnnualPiper...09atTheNewYorkPalaceHotelinNewYork,NewYork. ,, ...r,willbeavailabletorespondtoquestionsduringthepres...
(Date:11/24/2009)...asbeenmetforpatientswithadvanced-stage,orrecurrent...wire-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;...panyfocusedonendocrinetherapyandoncology,todayanno...rgetedcytotoxicpeptideconjugate,AEZS-108(formerlyA...lcancer.Inapersonalizedhealthcareapproach,thestudy...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...TON, July 29 Scimitar Equity, LLC issues a review...ard: VOQP), entitled, "510k,Application Submitted ...cta(TM) Focuses Milestones and Share Price Appreci...tp://www.scimitarequity.com ., VioQuest Pharmaceu...,dedicated to becoming a recognized leader in the ...
... CARLOS, Calif., July 29 Nuvelo, Inc.,(Nasdaq: N...st subject in a,single-center, Phase 1 trial of re...lead compound from its Wnt Therapeutics Program. T...ding dose (SAD) trial will,determine the safety, t...ous (IV) administration of NU206, in approximately...
... "As one of AFRA,s fou...ceive its accreditation," remarks Gregoire Le... "For more than 10 years our vision in the gl...n, JMV Aviation and BAR) has been to operate in a ... to our five locations in France as well as facili...
Other Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 3First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 2First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 3First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 4
RDF (R106-05) from European Collection of Cell Cultures (ECACC)
...The Brownlee Precision Model 440 incorporates four...rcuitry in a friendly easy-to-use instrument. Each...er, an 8-pole Bessel lowpass filter, a highpass fi...ols. A control knob sets the amplifier parameters ...
REK (R102-05) from European Collection of Cell Cultures (ECACC)
PCAEC (P300-05) from European Collection of Cell Cultures (ECACC)
Biology Products: